Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.36 |
| ▸ | CA9 | Q16790 | 13/20 | 0.36 |
| ▸ | CA1 | P00915 | 12/20 | 0.36 |
| ▸ | CA12 | O43570 | 11/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PTN | P21246 | 1/20 | 0.33 |
| ▸ | MDK | P21741 | 1/20 | 0.33 |
| ▸ | BDNF | P23560 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | MMP12 | P39900 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24454398 | 0.87 | MAPK1 (0.36) | CA2CA9CA1CA12MAPK1 | |
| SCHEMBL22928394 | 0.87 | LMNA (0.43) | CA2CA9CA1CA12MAPK1 | |
| SCHEMBL29557204 | 0.77 | LMNA (0.53) | CA2CA9CA1CA12LMNA | |
| SCHEMBL8747631 | 0.75 | LMNA (0.56) | CA2CA9CA1CA12LMNA | |
| SCHEMBL7899944 | 0.75 | LMNA (0.56) | CA2CA9CA1CA12LMNA | |
| SCHEMBL14302583 | 0.75 | LMNA (0.56) | CA2CA9CA1CA12LMNA | |
| SCHEMBL15165006 | 0.75 | LMNA (0.56) | CA2CA9CA1CA12LMNA | |
| SCHEMBL16340705 | 0.75 | LMNA (0.56) | CA2CA9CA1CA12LMNA | |
| SCHEMBL13903997 | 0.75 | LMNA (0.56) | CA2CA9CA1CA12LMNA | |
| SCHEMBL4110433 | 0.75 | LMNA (0.56) | CA2CA9CA1CA12LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162252-A1 | SYNTHESIS OF 6-AZIDO-6-DEOXY-2-N-ACETYL-HEXOSAMINE-NUCLEOSIDE DIPHOSPHATE | SYNAFFIX B.V. (NL) | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162252-A1 | SYNTHESIS OF 6-AZIDO-6-DEOXY-2-N-ACETYL-HEXOSAMINE-NUCLEOSIDE DIPHOSPHATE | FUT6, NANS, B3GNT2 | CA2 3391/4885CA9 2065/4885CA1 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.